Jump to content

Iressa - Latest Finding


Recommended Posts

Could anyone tell me the meaning of "95% CI, 28.8-31.1"???

Data presented at the American Society of Clinical Oncology (ASCO)

40th Annual Meeting

NEW ORLEANS, June 6 /PRNewswire-FirstCall/ -- Final data from more than 21,000 non-small-cell lung cancer (NSCLC) patients who received the oral cancer drug IRESSA® (gefitinib) through AstraZeneca's pre-approval expanded access program (EAP) in the United States were presented today at the American Society of Clinical Oncology (ASCO) meeting. The one-year survival rate in patients treated with IRESSA on a compassionate basis was reported as 29.9%.

This data set represents the largest reporting to date of clinical use of an

agent in the epidermal growth factor receptor (EGFR) class.

The IRESSA EAP was initiated to allow access to the drug while it was

pending U.S. Food and Drug Administration (FDA) approval. The program ran from August 2000 to July 2003 in the United States and enrolled 23,383 advanced (stage III/IV) non-small-cell lung cancer patients who had exhausted all approved treatment options or were unable to tolerate chemotherapy.

"Because the EAP enabled the use of IRESSA outside of a formal clinical

trial setting, it provides a unique look at patient impact in a true clinical

setting," said Judith Ochs M.D., Senior Medical Director, AstraZeneca LP, lead author of the study. The data presented followed 21,064 patients who received greater than or equal to 1 dose of IRESSA. Patient demographics included 9,979 women and 11,040 men. Median age was 67 years and 72.7% of patients had stage IV disease. Median survival was 5.3 months (95% CI, 5.1 - 5.5 mo) and 1-year survival was 29.9% (95% CI, 28.8 - 31.1). Duration of therapy and survival were measured from the start of initial therapy to the last resupply date for ongoing patients or the date of last dose for withdrawn patients. For surviving patients who withdrew, periodic follow-up data were not collected,

and patients were censored for survival at withdrawal until death was


In the EAP 2.3% of patients reported a serious treatment-related adverse (AE) event; 1.1% discontinued therapy due to a serious drug-related AE, and 0.3% had an investigator-assessed, drug-related death.

Link to comment
Share on other sites

It means confidence interval. It is a statistical term. I haven't had stats since college so I can't really explain it too well.

I believe it means that they confidence interval is 95% and the range is 28.8-31.1%. This means that at least 28.8% improved and at most 31.1% improved and that they are 95% sure of this.

http://www.cas.lancs.ac.uk/glossary_v1. ... nfinterval

http://davidmlane.com/hyperstat/confide ... rvals.html

The only concern I would have with this study is that it was done by AstraZeneca (the manufacturer of Iressa)

Link to comment
Share on other sites

The value 95% refers to the level of confidence. It is the most commonly used level of confidence. The values 28.8 - 31.1 represent the confidence interval. 95% of the values for mean survival from the population sampled will fall between 28.8 and 31.1 months. 5% of the population samples will have mean survivals of less than 28.8 or more than 31.1 months. This is what I understand and hope it helps.



Link to comment
Share on other sites

Join the conversation

You can post now and register later. If you have an account, sign in now to post with your account.

Reply to this topic...

×   Pasted as rich text.   Restore formatting

  Only 75 emoji are allowed.

×   Your link has been automatically embedded.   Display as a link instead

×   Your previous content has been restored.   Clear editor

×   You cannot paste images directly. Upload or insert images from URL.

  • Create New...

Important Information

By using this site, you agree to our Terms of Use.